0
Original Research: ASTHMA |

Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma*

Eric Bateman, MD, FRCP; Jill Karpel, MD, FCCP; Thomas Casale, MD; Sally Wenzel, MD, FCCP; Donald Banerji, MD
Author and Funding Information

*From the University of Cape Town (Dr. Bateman), Cape Town, South Africa; North Shore University Hospital (Dr. Karpel), Long Island, NY; Creighton University (Dr. Casale), Omaha, NE; and National Jewish Medical Research Center (Dr. Wenzel), Denver, CO; and Aventis Pharmaceuticals (Dr. Banerji), Bridgewater, NJ.

Correspondence to: Eric Bateman, MD, FRCP, University of Cape Town Lung Institute, PO Box 34560, Groote Schuur 7937, Cape Town, South Africa; e-mail: ebateman@uctgsh1.uct.ac.za



Chest. 2006;129(5):1176-1187. doi:10.1378/chest.129.5.1176
Text Size: A A A
Published online

Study objectives: Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS). The potential of ciclesonide, a novel ICS, to reduce OCS use in patients with severe, persistent asthma was evaluated in this study.

Design: A phase III, 12-week, international, multicenter, double-blind, placebo-controlled, parallel-group study.

Patients: Adult and adolescent patients (≥ 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.

Interventions: Patients were randomized to receive ciclesonide (640 μg/d or 1,280 μg/d [ex-actuator]) bid or placebo for 12 weeks. Weekly evaluations determined eligibility for prednisone dose reduction based on predetermined criteria.

Measurements and results: The prednisone dose was significantly reduced by 47% and 63% in the groups receiving ciclesonide, 640 μg/d, and ciclesonide, 1,280 μg/d, respectively, vs an increase of 4% in the placebo group (both p ≤ 0.0003) at week 12. By week 12, prednisone was discontinued by approximately 30% of patients in the ciclesonide-treated groups, vs 11% of patients in the placebo group (both p ≤ 0.04). FEV1 improved significantly at week 12 in the ciclesonide treatment groups vs placebo (p < 0.03). The occurrence of local and systemic AEs was comparable between all treatment groups.

Conclusion: Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543